Nonprofit sues FDA to force Provenge approval

Share this article:
A nonprofit patient advocacy group has filed suit against the FDA in an Ohio federal court seeking to overturn the agency's decision earlier this year to not approve Dendreon's prostate cancer vaccine Provenge.

The lawsuit, filed by Ohio-based Care to Live, which includes some Dendreon investors, alleges that the FDA in May failed to follow an advisory committee recommendation to approve Provenge and instead asked the company for more information.

The group argues that Provenge's Biologics License Application approval was derailed by Richard Pazdur, director of the FDA drug center's oncologic drugs division, as part of a bureaucratic turf battle with the FDA's biologics center over who would control all oncology therapies.

It charges that this led him to place two conflicted panel members on an advisory committee that reviewed the drug.

The suit also alleges that FDA commissioner Andrew von Eschenbach was in support of an earlier biologics center recommendation to approve Provenge, but instead gave in to Pazdur's demands after he “executed a successful coup d'etat.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.